Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garth Powis

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Molecular Cancer Therapeutics|May 14, 2004
Hypoxia inducible factor-1alpha as a cancer drug targetGarth Powis, Lynn Kirkpatrick
Carcinogenesis|October 12, 2002
The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cellsBryan Husbeck, Garth Powis
Trends in Biochemical Sciences|July 24, 2012
Passing the baton: the HIF switchMei Yee Koh, Garth Powis
Current Opinion in Pharmacology|July 6, 2007
Thioredoxin signaling as a target for cancer therapyGarth Powis, D Lynn Kirkpatrick
Molecular Aspects of Medicine|February 24, 2010
Inhibitors of phosphatidylinositol-3-kinase in cancer therapyNathan T Ihle, Garth Powis
Cell Cycle (Georgetown, Tex.)|April 21, 2009
HAF : the new player in oxygen-independent HIF-1alpha degradationMei Yee Koh, Garth Powis
Molecular Cancer Therapeutics|January 14, 2009
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapyNathan T Ihle, Garth Powis
Antioxidants & Redox Signaling|March 18, 2016
Clinically Evaluated Cancer Drugs Inhibiting Redox SignalingD Lynn Kirkpatrick, Garth Powis
Current Cancer Drug Targets|December 20, 2003
Hypoxia inducible factor as a cancer drug targetSarah J Welsh, Garth Powis
Current Opinion in Drug Discovery & Development|January 5, 2010
The biological effects of isoform-specific PI3-kinase inhibitionNathan T Ihle, Garth Powis
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Molecular Cancer Therapeutics|May 14, 2004
Hypoxia inducible factor-1alpha as a cancer drug targetGarth Powis, Lynn Kirkpatrick
Carcinogenesis|October 12, 2002
The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cellsBryan Husbeck, Garth Powis
Trends in Biochemical Sciences|July 24, 2012
Passing the baton: the HIF switchMei Yee Koh, Garth Powis
Current Opinion in Pharmacology|July 6, 2007
Thioredoxin signaling as a target for cancer therapyGarth Powis, D Lynn Kirkpatrick
Molecular Aspects of Medicine|February 24, 2010
Inhibitors of phosphatidylinositol-3-kinase in cancer therapyNathan T Ihle, Garth Powis
Cell Cycle (Georgetown, Tex.)|April 21, 2009
HAF : the new player in oxygen-independent HIF-1alpha degradationMei Yee Koh, Garth Powis
Molecular Cancer Therapeutics|January 14, 2009
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapyNathan T Ihle, Garth Powis
Antioxidants & Redox Signaling|March 18, 2016
Clinically Evaluated Cancer Drugs Inhibiting Redox SignalingD Lynn Kirkpatrick, Garth Powis
Current Cancer Drug Targets|December 20, 2003
Hypoxia inducible factor as a cancer drug targetSarah J Welsh, Garth Powis
Current Opinion in Drug Discovery & Development|January 5, 2010
The biological effects of isoform-specific PI3-kinase inhibitionNathan T Ihle, Garth Powis
Pageof 10